Low LeverageA low absolute debt load relative to equity materially reduces financial distress risk and preserves flexibility to finance clinical development or commercialization through non-distressed channels. This conservative leverage profile supports multi-quarter R&D execution and strategic options.

Proprietary IDOSE PlatformAn integrated treatment-planning and light-delivery platform creates a structural product advantage: it raises switching costs, supports reproducible clinical outcomes, and can form the basis for regulatory and clinical adoption in targeted tumor indications over the coming quarters.

Scalable Margin PotentialProfitability setbacks stem mainly from lack of scalable revenue rather than collapsing unit economics. If clinical adoption and sales execution accelerate, gross margins could scale favorably, allowing operating leverage to meaningfully improve over multiple quarters.

Bears Say

Minimal RevenueSustained near-zero top-line prevents absorption of fixed R&D and G&A costs, making profitability dependent on successful commercialization or recurrent financing. Over 2-6 months this constraint limits reinvestment capacity and prolongs reliance on external capital.

Negative Free Cash FlowAccelerating negative free cash flow indicates increasing cash burn and shortens the time to next meaningful financing. Persistent negative FCF constrains organic growth, risks program delays, and raises dilution or financing cost risk over the medium term.

Shrinking Equity BufferA declining equity base reflects repeated losses and capital raises, reducing the balance-sheet cushion for unforeseen setbacks. Continued erosion increases the probability of further fundraising, which can dilute current holders and complicate long-term funding plans.

SPEC FAQ

What was SpectraCure AB’s price range in the past 12 months?

SpectraCure AB lowest stock price was kr0.08 and its highest was kr1.19 in the past 12 months.

What is SpectraCure AB’s market cap?

SpectraCure AB’s market cap is kr48.50M.

When is SpectraCure AB’s upcoming earnings report date?

SpectraCure AB’s upcoming earnings report date is May 19, 2026 which is in 57 days.

How were SpectraCure AB’s earnings last quarter?

SpectraCure AB released its earnings results on Feb 19, 2026. The company reported -kr0.018 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.018.

Is SpectraCure AB overvalued?

According to Wall Street analysts SpectraCure AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does SpectraCure AB pay dividends?

SpectraCure AB does not currently pay dividends.

What is SpectraCure AB’s EPS estimate?

SpectraCure AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does SpectraCure AB have?

SpectraCure AB has 570,602,840 shares outstanding.

What happened to SpectraCure AB’s price movement after its last earnings report?

SpectraCure AB reported an EPS of -kr0.018 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of SpectraCure AB?

Currently, no hedge funds are holding shares in SE:SPEC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

SpectraCure AB

SpectraCure AB (SPEC) is a medical technology company operating primarily in the field of cancer treatment. The company specializes in developing and commercializing innovative systems for photodynamic therapy (PDT), a minimally invasive treatment approach that uses light-sensitive drugs to target and destroy cancer cells. SpectraCure's core product is its proprietary interstitial PDT (IPDT) system, designed to treat solid tumors such as prostate cancer. The company is committed to advancing cancer care by providing effective and less invasive treatment options.